STEFANOVICH ROBERT 4
4 · Cryoport, Inc. · Filed Mar 16, 2026
Research Summary
AI-generated summary of this filing
Cryoport (CYRX) CFO Robert Stefanovich Exercises Options, Sells Shares
What Happened
Robert Stefanovich, Chief Financial Officer of Cryoport (CYRX), exercised 87,188 options on March 12, 2026 at an exercise price of $1.87 (cost $163,042) and contemporaneously sold shares. He sold 38,700 shares on March 12 at a weighted average price of $7.76 for $300,386, and sold 2,743 shares on March 16 at $8.00 for $21,944 — total proceeds from sales $322,330. On March 14 he was also granted restricted stock rights (27,413 shares) and an additional contingent award (82,240 RS rights) that vest over time.
Key Details
- Transactions: Exercise (M) of 87,188 shares on 2026-03-12; sales (S) of 38,700 shares on 2026-03-12 (weighted avg $7.76) and 2,743 shares on 2026-03-16 ($8.00); awards (A) of 27,413 and 82,240 restricted stock rights on 2026-03-14.
- Dollar amounts: Exercise cost $163,042; sales proceeds $300,386 (3/12) + $21,944 (3/16) = $322,330.
- Shares owned after transaction: Not specified in the provided filing summary.
- Notable footnotes: Sale proceeds were used to pay the option exercise price and withholding taxes (F1). The 3/12 sale price is a weighted average of trades between $7.725–$7.83 (F2). The 3/14 awards are restricted stock rights that vest in four equal annual installments beginning March 14, 2027 (F3). Some shares were sold to cover tax withholding on vesting (F4). Vesting schedules for options/awards noted in F5–F6.
- Timeliness: The report was filed on 2026-03-16 covering a 2026-03-12 transaction; Form 4 is generally due within two business days, so the filing appears later than that window for the March 12 activity.
Context
This was effectively a cashless exercise: options were exercised and shares were sold with proceeds used to cover the exercise price and taxes (per F1 and F4). The awards reported on March 14 are contingent restricted stock rights with multi-year vesting and do not represent immediately tradable shares. These kinds of exercised-and-sold transactions are commonly used to satisfy tax and exercise obligations and are not, by themselves, a clear bullish signal about insider views.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-03-12$1.87/sh+87,188$163,042→ 294,401 total - Sale
Common Stock
[F1][F2]2026-03-12$7.76/sh−38,700$300,386→ 255,701 total - Award
Common Stock
[F3]2026-03-14+27,413→ 283,114 total - Sale
Common Stock
[F4]2026-03-16$8.00/sh−2,743$21,944→ 280,371 total - Exercise/Conversion
Options to purchase common stock
[F5]2026-03-12−87,188→ 0 totalExercise: $1.87Exp: 2026-05-06→ Common Stock (87,188 underlying) - Award
Stock Option (right to buy)
[F6]2026-03-14+82,240→ 82,240 totalExercise: $8.60Exp: 2033-03-14→ Common Stock (82,240 underlying)
Footnotes (6)
- [F1]The proceeds of the sale of Common Stock were used to pay the exercise price and withholding taxes due upon exercise of the Stock Option reported in this Form 4.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.725 to $7.83, inclusive.
- [F3]Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027.
- [F4]Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
- [F5]1/48 of options vested on the 6th of each month for forty-eight months beginning May 6, 2016.
- [F6]1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.